Modeling the epidemiologic impact of age-targeted vaccination for drug-resistant tuberculosis

IF 15.8 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Resistance Updates Pub Date : 2024-11-13 DOI:10.1016/j.drup.2024.101172

Pei-Yao Zhai , Zhi-Xian Chen , Ting Jiang , Jian Feng , Bin Zhang , Xiao Zang , Yan-Lin Zhao , Gang Qin

引用次数: 0

Abstract

This study used a calibrated mathematical model to evaluate age-specific tuberculosis (TB) vaccination strategies, for drug-resistant (DR)-TB management in China. Prioritizing elderly vaccination significantly reduced multidrug-resistant or rifampicin-resistant TB incidence and mortality, while avoiding the need for second-line treatment, offering a promising approach to mitigate DR-TB burden by 2050.

查看原文本刊更多论文

针对抗药性结核病的年龄目标疫苗接种的流行病学影响建模。

本研究利用校准数学模型评估了针对特定年龄段的结核病（TB）疫苗接种策略，以管理中国的耐药结核病（DRTB）。优先为老年人接种疫苗可显著降低耐多药或耐利福平结核病的发病率和死亡率，同时避免二线治疗的需要，为到2050年减轻耐药结核病的负担提供了一种可行的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Resistance Updates 医学-药学

CiteScore

26.20

自引率

11.90%

发文量

审稿时长

29 days

期刊介绍： Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research